Abstract 50P
Background
As we enter an aging society, the number of elderly breast cancer patients is increasing. We assessed the prognostic factors of recurrence or metastasis for breast cancer patients over the age of 65 by analyzing the characteristics of tumor and long-term clinical outcomes.
Methods
Data were retrospectively analyzed for 286 breast cancer patients aged 65 years and older who underwent treatment in the Pusan national university hospital and Pusan national university Yangsan hospital from 2008 to 2014. Dividing two groups as the patients with event such as recurrence or metastasis and those who without it, the Cox regression model was used to examine the risk factors of recurrence or metastasis.
Results
Among 286 patients with invasive breast cancer, forty three patients (15.0%) have been found to have recurrence or distant metastasis during median follow-up period of 61 months. The poor prognosis was found in the advanced stage of breast cancer, patients without endocrine therapy and low Allred scores of estrogen receptor.Table: 50P
Variable | Hazard ratio | P-value | 95% CI |
---|---|---|---|
Stage | 1.78 | <0.0001 | (1.39, 2.28) |
Endocrine therapy | 0.04 | 0.0002 | (0.01, 0.23) |
Estrogen receptor | 1.34 | 0.0076 | (1.08, 1.66) |
Conclusions
The advanced stage of breast cancer was poor prognosis in the elderly breast cancer patients. Moreover, endocrine therapy should be performed on elderly breast cancer patients with high Allred score of estrogen receptor because it is good for prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract